On Oct. 29, 2020, OncoSec Medical announced that the FDA had approved the Investigational New Drug (IND) application for a first-in-human Phase 1 trial for CORVax12, a novel DNA-encodable vaccine against SARS-CoV-2 that the Company is developing with Providence Cancer Institute, a part of Providence St. Joseph Health.

CORVax combines OncoSec’s immuno-stimulant IL-12 expression platform, TAVOﾙ (tavokinogene telseplasmid), with a DNA-encodable stabilized trimeric SARS-CoV-2 spike glycoprotein developed by researchers at the National Institute of Allergy and Infectious Diseases, and which was licensed to OncoSec on a non-exclusive basis.